IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v19y2022i7p4156-d784378.html
   My bibliography  Save this article

Single-Pill Combination to Improve Hypertension Treatment: Pharmaceutical Industry Development

Author

Listed:
  • Magdalena Paczkowska-Walendowska

    (Department of Pharmacognosy, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland)

  • Szymon Sip

    (Department of Pharmacognosy, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland)

  • Rafał Staszewski

    (Department of Hypertension, Angiology and Internal Medicine, Poznan University of Medical Sciences, Długa 1/2, 61-848 Poznań, Poland)

  • Judyta Cielecka-Piontek

    (Department of Pharmacognosy, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland)

Abstract

Multiple illness is an increasingly common phenomenon. Its consequence is the need for polytherapy, which is particularly common among people suffering from arterial hypertension. The development of combined preparations (containing at least two API-active pharmaceutical ingredients) dedicated to the treatment of hypertension is a response to increased compliance, especially in elderly patients. In our work, we describe in particular the possibilities of using β-adrenergic receptors blockers and angiotensin-converting enzyme inhibitors in combinations. The combinations of APIs are used as single pills in patients with arterial hypertension with concomitant diseases such as hyperlipidemia; blood coagulation problems and diabetes mellitus were also discussed successively. Pharmacoeconomic analysis for the API combinations shown is also presented. As a final conclusion, numerous benefits of using the combined preparations should be indicated, especially by the elderly and/or in patients with coexistence of other diseases.

Suggested Citation

  • Magdalena Paczkowska-Walendowska & Szymon Sip & Rafał Staszewski & Judyta Cielecka-Piontek, 2022. "Single-Pill Combination to Improve Hypertension Treatment: Pharmaceutical Industry Development," IJERPH, MDPI, vol. 19(7), pages 1-18, March.
    • Handle: RePEc:gam:jijerp:v:19:y:2022:i:7:p:4156-:d:784378
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/19/7/4156/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/19/7/4156/
    Download Restriction: no
    ---><---

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:19:y:2022:i:7:p:4156-:d:784378. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.